F D C

F D C EBITDA per Share

The EBITDA per Share of F D C (FDC.NS) as of Nov 10, 2026 is 19.95 INR. In the previous year, EBITDA per Share was 20.84 INR — a change of -4.27% (lower).

EBITDA per Share

19.95INR

YoY

-4.27%

Last updated:

EBITDA per Share of F D C is 2025 19.95 INR. EBITDA per Share of F D C was 2024 20.84 INR. It decreases by -4.27% lower compared to the previous year.

The F D C EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
13.34 INR
Jan 1, 2019
13.36 INR
Jan 1, 2020
19.58 INR
Jan 1, 2021
19.62 INR
Jan 1, 2022
15.29 INR
Jan 1, 2023
15.42 INR
Jan 1, 2024
20.84 INR
Jan 1, 2025
19.95 INR
The F D C EBITDA per Share history
YEAREBITDA per ShareYoY
19.95INR-4.27%
20.84INR+35.18%
15.42INR+0.82%
15.29INR-22.07%
19.62INR+0.22%
19.58INR+46.54%
13.36INR+0.20%
13.34INR-8.61%
14.59INR+3.87%
14.05INR+14.92%
12.22INR-4.10%
12.75INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

F D C Stock analysis

What does F D C do? FDC Ltd. generates revenue through the manufacturing and distribution of pharmaceutical generics, formulations, and active pharmaceutical ingredients (APIs). The company produces specialized products such as oral rehydration salts (ORS) and functional foods and beverages, targeting therapeutic segments including anti-infectives, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, and analgesics. Its branded products like Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm are sold to healthcare providers and consumers across these segments. The company's APIs, including Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate, and Timolol Maleate, support its formulation business. FDC Ltd. distributes its products through its manufacturing plants, serving both domestic and international markets with a focus on cost-effective generic medicines and specialized formulations. FDC Ltd. targets healthcare providers, hospitals, and retail pharmacies as key buyers of its branded pharmaceuticals and functional products. The company's product portfolio spans multiple therapeutic areas, with brands like Zifi for respiratory conditions and Electral for rehydration, catering to diverse consumer needs in the Indian pharmaceutical market. F D C is one of the most popular companies on Eulerpool.

Frequently Asked Questions about F D C stock

EBITDA per Share of F D C is 19.95 INR in 2025.

EBITDA per Share of F D C changed from 20.84 INR to 19.95 INR, representing a -4.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share F D C since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — F D C

All Key Metrics — F D C